Search research articles
Contact Us
Filters
Showing results (71-80 of 114) with videos related to
Page
of 12
Sort By:
Cancer Treatment and Research Communications
|
April 27, 2021
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis
S Ponce Aix, S Novello, E B Garon, et al.
British Journal of Cancer
|
December 17, 2008
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
M J McKeage, J Von Pawel, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S Novello, B Besse, E Felip, et al.
Diagnostic Pathology
|
July 29, 2015
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
I Watermann, B Schmitt, F Stellmacher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
G Mountzios, J Remon, S Novello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2023
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
E Felip, N Altorki, C Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>
A-M C Dingemans, M Früh, A Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
M Früh, C M Panje, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R Rosell, G Robinet, A Szczesna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2012
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
M Kreuter, J Vansteenkiste, J R Fischer, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 114) with videos related to
Sort By:
Page
of 12
Cancer Treatment and Research Communications
|
April 27, 2021
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis
S Ponce Aix, S Novello, E B Garon, et al.
British Journal of Cancer
|
December 17, 2008
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
M J McKeage, J Von Pawel, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S Novello, B Besse, E Felip, et al.
Diagnostic Pathology
|
July 29, 2015
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
I Watermann, B Schmitt, F Stellmacher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration
G Mountzios, J Remon, S Novello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2023
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
E Felip, N Altorki, C Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2021
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>
A-M C Dingemans, M Früh, A Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 3, 2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
M Früh, C M Panje, M Reck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R Rosell, G Robinet, A Szczesna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2012
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
M Kreuter, J Vansteenkiste, J R Fischer, et al.
Page
of 12